Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
IRadimed IRMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | IRMD | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 68B | 77B | LMAT |
| Benjamin Graham | 89A | 89A | Tie |
| Philip Fisher | 92A | 81C | IRMD |
| Peter Lynch | 76B | 67B | IRMD |
| Joel Greenblatt | 65C | 56D | IRMD |
| Charlie Munger | 78B | 68D | IRMD |
| Terry Smith | 75B | 69D | IRMD |
| Metric | IRMD | LMAT |
|---|---|---|
| Market cap | $1.18B | $2.23B |
| P/E (TTM) | 50.4x | 37.1x |
| EV/EBIT | 43.4x | 36.6x |
| ROIC (TTM) | 21.38% | 9.43% |
| Gross margin | 76.84% | 72.39% |
| Net margin | 27.36% | 24.35% |
| Revenue CAGR 5y | 18.99% | 12.75% |
| EPS CAGR 5y | 23.53% | 19.04% |
| Debt / Equity | - | 0.5x |
| Dividend yield | 1.33% | 0.84% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IRMD leads on
LMAT leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.